Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

">EUR328 million). The acquisition will be funded out of Shire's current cash resources.

It is anticipated that the offer to Movetis' shareholders will open for acceptance in September. The offer is contingent upon the fulfillment of certain conditions, including receipt of acceptances in respect of at least 90% of the shares that are the subject of the offer and that Movetis does not suffer a material adverse change before the results of the offer are published.

Shire has entered into agreements with institutional shareholders in which they have unconditionally committed 38.9% of Movetis' existing ordinary share capital to the offer.

Once finalized, the prospectus will be published and circulated to Movetis' shareholders, and details will be available on www.shire.com and www.movetis.com. No action will be taken to permit a public tender offer in any other jurisdiction than Belgium. This press release does not constitute an invitation to sell or the solicitation of an offer to buy any security.

Deutsche Bank AG is acting as financial adviser to Shire.

Strategic Rationale for the Transaction

The acquisition adds to Shire's portfolio of treatments for GI conditions with high unmet need and prescribed by specialist physicians. Shire's stated strategic focus on GI led to the establish
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... London, UK (PRWEB) July 10, 2014 ... inaugural 21st Century Medicine Forum on ‘Commercialising Longevity ... scientists and entrepreneurs to the London Bioscience Innovation ... Biogerontology Research Foundation and Aging Analytics Ltd. The ... and investment in translational research for age-related disease, ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Gov. Jim Doyle and the Republican-led Legislature are still ... treat public school districts across Wisconsin. Doyle thinks he ... Republicans believe Doyle abused his veto power and put ... over how to pay for public education appears destined ...
... Madison, Wis. You work hard. You've developed ... recognized within your company. And you just got fired. Or ... bought out. Whatever. The bottom line is that that sweet ... a sudden lost-in-a-dark-woods turn. , ,I'd like to say this ...
... universal presentation tool that isn't universally loved. But Microsoft's PowerPoint ... shouldn't be if its use in distance learning is to ... Horton, a partner in the Denver-based William Horton Consulting. ... sneer, smile and say, `That's nice,'" said Horton, who, with ...
Cached Biology Technology:Before deciding how to pay for K-12 schools, let's determine what to buy 2Before deciding how to pay for K-12 schools, let's determine what to buy 3When doing a good job isn't good enough 2When doing a good job isn't good enough 3Bringing distance learning alive 2
(Date:7/11/2014)... WASH. July 11, 2014 Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Biometrics Technology Market - Industry Analysis Size ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... and crimes has created a need for high level ... used for personnel authentication such as username and passwords, ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Researchers at Cold Spring Harbor Laboratory (CSHL) announced ... RNAs. At the same time, they reported that their ... pathway for RNA processing in which these and possibly ... part of a multinational project called ENCODE, also provided ...
... U.S. National Science Foundation and the U.S. Implementing Organization ... occasion of the research vessel JOIDES Resolution sailing off ... Honolulu, after a complete transformation to modernize and upgrade ... JOIDES Resolution is the U.S. research vessel for exploring ...
... LAKE CITY As scientists celebrate 2009 as the ... psychology and other fields will gather at the University ... shaped human aggression and violence, from war to domestic ... violence, and how can we use this knowledge to ...
Cached Biology News:CSHL scientists find a new class of small RNAs and define its function 2CSHL scientists find a new class of small RNAs and define its function 3Ocean research officials hail completion of modernization for US scientific ocean drilling vessel 2The Evolution of Human Aggression: Feb. 25-27 conference 2The Evolution of Human Aggression: Feb. 25-27 conference 3The Evolution of Human Aggression: Feb. 25-27 conference 4
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: